Company Overview - Tongda Chuangzhi (Xiamen) Co., Ltd. is a national high-tech enterprise focused on R&D, production, and sales of consumer goods in sports outdoor, home living, and health care sectors [2][3]. - The company was established in 2016 and has built three major production bases in Xiamen, Shishi, and Malaysia [2]. - It has established long-term strategic partnerships with global leading multinational companies such as Decathlon, IKEA, Wagner, and YETI [3][6]. Product Range - The main product categories include: - **Sports Outdoor**: Products such as jump ropes, silicone sports water bottles, ice skates, skateboards, badminton rackets, and boxing equipment [4]. - **Home Living**: Electric tools, indoor home products like beach chairs, shoe cabinets, and kitchen utensils [4]. - **Health Care**: Electric toothbrushes, oral irrigators, and eye care devices [4]. Customer Base - The company has a strong customer resource advantage due to its partnerships with well-established brands, which provide a stable order flow and market share [6][11]. - The customer base includes major international brands, enhancing the company's influence and facilitating the development of new clients and fields [6][11]. Manufacturing Advantages - The company employs a multi-process and multi-tech integration production system, which is crucial for acquiring customer resources and capturing market share [9]. - It follows a "sales-driven production" model, aligning production with market demand, and has implemented "Industry 4.0" and "Smart Manufacturing 2025" strategies [9]. - The production system emphasizes high efficiency, quality, low cost, and flexible delivery, supported by a smart manufacturing framework that includes "unmanned workshops" and "intelligent warehousing" [9]. Industry Position and Competition - The global consumer goods industry is mature with numerous participants, characterized by a fragmented market in China [10][11]. - The company’s product structure and customer base are unique, with no direct competitors offering identical products [11]. - As the company strengthens its competitive advantages and steadily grows its performance, its market position and share are expected to improve [11].

编号：2026-002 证券代码：002487 证券简称：大金重工 大金重工股份有限公司 投资者关系活动记录表 | 3、从公开消息了解到，公司在西班牙也要进行本土化布局，具体考虑 | | --- | | 是？ | | 答：我们在丹麦、德国、西班牙陆续进行了码头布局，从而匹配区域 | | 项目的不同需求。公司海外码头的布局是针对项目需求而开展的，通 | | 过提升本地化的总装能力和服务能力，从而最终提高项目交付能力和 | | 盈利水平。 | | 4、在海外做产能布局，如何解决当地高成本的问题？ | | 答：首先，公司不仅是海风核心装备制造商，同样是海工综合服务解 | | 决方案系统提供商，已经实现通过延长产业链为下游客户提供如运输、 | | 母港、安装等更多服务；其次，我们会综合考虑并发挥国内和海外布 | | 局的协同优势，从而打造更强的竞争壁垒。 | | 5、公司陆续签下了带有服务端的项目订单，价值量提升很快，服务端 | | 折算为单吨是什么价格，定价逻辑是什么？ | | 答：服务端的定价需要根据具体项目需求而定，不能简单地去以吨计 | | 算。 | | 6、日韩市场的开拓进度如何？ | | 答：日本、韩国是 ...

Group 1: Strategic Adjustments - The company has initiated the sale of its non-core emergency rescue business to focus on its two main business segments: cardiovascular and health protection [2][3] - The cardiovascular business has entered a new phase of profitability, contributing over 100 million yuan in profit in 2025 after overcoming industry policy adjustments [3][4] - The health protection business underwent significant restructuring, including a strategic investment of 200 million USD and the acquisition of a thermal power enterprise to address energy supply issues [3][4] Group 2: Financial Performance - The net profit attributable to shareholders for the health protection division is projected to be between -650 million yuan and -850 million yuan, primarily due to operational losses and one-time tax payments [4][5] - The cardiovascular division achieved a turnaround from a loss of approximately 140 million yuan in 2024 to a profit exceeding 100 million yuan in 2025, driven by continuous R&D investment and management optimization [7][8] Group 3: Market Dynamics - The glove industry has experienced significant price fluctuations, with a recovery in demand leading to a rise in production rates to 90%-100% by early 2024, resulting in profitability by May 2024 [12][13] - The company has implemented strategies to manage raw material price volatility, ensuring cost-effective procurement to maintain competitive advantages [14] Group 4: Product Development and Innovation - The company has focused on developing innovative products in the cardiovascular sector, including a new drug-coated balloon technology that has shown promising results in clinical trials [9][10] - The polyurethane gloves developed in collaboration with Wanhua Chemical have gained recognition for their superior breathability and cleanliness, positioning the company to capture significant market potential [14]

Group 1: Company Overview and Strategy - The company aims to strengthen its position as the only blood product platform within the China Resources Health sector during the 14th Five-Year Plan, focusing on "doing strong, optimizing, and expanding" [3] - The strategy includes enhancing plasma collection, terminal control, R&D innovation, and exploring international markets [3][4] Group 2: Plasma Collection and Growth Projections - The total plasma collection for 2025 is projected to be approximately 662 tons, representing a year-on-year growth of about 5% [4] - The integration of Green Cross (China) is expected to yield a plasma collection growth rate exceeding 10%, with an absolute increase of over 10 tons [4] Group 3: Product Development and Regulatory Approvals - The company has received production approvals for 10% intravenous immunoglobulin and tetanus immunoglobulin, with clinical trials for 20% subcutaneous immunoglobulin progressing steadily [3][5] - High-concentration intravenous immunoglobulin (pH4) has been officially approved for sale as of May 2025 [5][6] Group 4: Market Dynamics and Pricing Strategy - Blood product prices are anticipated to face downward pressure due to market competition, with price adjustments expected in 2026 following the Guangdong alliance procurement [8] - The company plans to enhance terminal control and refine management of agents to improve market influence and brand recognition [8] Group 5: Expansion and Regulatory Challenges - The number of plasma collection stations has significantly increased during the 14th Five-Year Plan, but growth may slow during the 15th Five-Year Plan due to rising industry concentration [9] - The establishment of new plasma stations is subject to government approvals, which introduces uncertainty [9] Group 6: Business Focus and Divestitures - The company has decided to focus solely on blood product development, transferring 80% of the equity in Boya Xinhao, which will no longer be included in the consolidated financial statements [10][11]

Group 1: Company Performance in 2025 - The company launched new products such as "China's Good Dumplings" and "Golden Ratio Dumplings," leading to rapid revenue growth from new products [2] - The soup product line introduced three series targeting different consumer needs, contributing to overall sales improvement [2] - The direct sales channel showed significant improvement, with a notable reduction in revenue decline and profit losses [3] Group 2: Sales Channel Optimization - The company implemented organizational adjustments in the direct sales channel, enhancing management efficiency through multi-dimensional data analysis [3] - Collaboration with major retail systems was deepened, resulting in improved service capabilities and profitability [3] - The company capitalized on opportunities in the supermarket sector by expanding customized product offerings [3] Group 3: Growth Opportunities for 2026 - Continuous product development and upgrades are planned to enrich the product matrix and enhance competitiveness [3] - The company aims to deepen customized cooperation in the direct sales channel and expand into previously uncovered regional chains [3] - The membership supermarket business is expected to achieve significant growth due to improved product strength and service response [3] Group 4: Future Business Directions - The company views instant retail as a growing channel and plans to strategically develop this area in collaboration with platforms like Taobao and Meituan [3] - The company has obtained necessary certifications for overseas investment and is progressing with its international expansion plans [3]

Group 1: Company Overview - The company is Hunan Jiutian Pharmaceutical Co., Ltd., with stock code 300705 and bond code 123223 [1][2]. Group 2: Innovation and Product Development - The company is developing innovative external preparations, including the acne treatment JIJ02 gel, which is currently in clinical development [2]. - In the traditional Chinese medicine sector, the company has submitted production applications for the pepper pain relief gel patch and has received clinical trial approval for JIZM01 and JIZM02 [2][3]. - The company employs a dual approach of independent research and project introduction to enhance its innovative drug pipeline [2][4]. Group 3: Strategic Focus for 2026 - In 2026, the company aims to stabilize its existing business while driving innovation through a dual strategy [4]. - Key initiatives include promoting the sales of existing products like the Loxoprofen Sodium Gel Patch and enhancing brand recognition through the new "Jiutian Pain Relief Mr." branding [4]. - The company plans to expand into high-end pharmaceutical excipients while adhering to GMP management policies [4]. Group 4: Market Performance and Strategies - Despite a sluggish external market, the company has maintained stable growth in its external market by leveraging a professional OTC team of over 200 members [5]. - The company focuses on brand-driven strategies and patient education to enhance brand recognition and consumer loyalty [5]. - The integrated supply chain of "formulations + raw materials + pharmaceutical excipients" provides quality assurance and cost competitiveness [5]. Group 5: Acquisition Strategy - The company is open to evaluating and acquiring high-quality products or assets that align with its strategic development needs [7]. Group 6: Product Matrix - The company has established a clear and advantageous external product matrix, including products like Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, which have significant competitive advantages [7]. - The Ketoprofen Gel Patch is a key exclusive product under medical insurance, while the traditional Chinese medicine sector features unique products like the Strong Waist and Bone Strengthening Patch [7].

编号：2026-001 证券代码：301448 证券简称：开创电气 浙江开创电气股份有限公司 投资者关系活动记录表 投资者关系 活动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他： 参与单位名称 及人员姓名 方正证券研究所研究员 张其超 时间 2026 年 2 月 3 日（周二）14:00~16:00 地点 公司会议室 公司接待人员 姓名 公司董事、副总经理、董事会秘书张垚嗣先生 投资者关系活 动主要内容 介绍 一、公司目前重点发展的业务方向是什么，请简单介绍一 下。 公司主要从事手持式电动工具整机及核心零部件的研发、 生产、销售及贸易，公司控股子公司燕谷（北京）机器人智能 技术有限公司（以下简称"燕谷机器人公司"）目前处于机器 人前期研发阶段，是公司新的战略布局。 二、燕谷机器人公司与清华大学的合作投入资金情况及进 展情况如何？ 燕谷机器人公司跟清华大学合作正常进展中，第一笔研发 经费 1500 万元按照合作协议已支付清华大学。2026 年 1 月初 已召开联合研究中心管委会第一次会议，通过了联合机构章程 | | 和管委会相关机制，同时决定批准了 ...

证券代码：300748 证券简称：金力永磁 2、请介绍公司的当前产能和包头三期建设情况？ 答：在董事会战略引领以及全员努力下，公司已达成于 2021 年 3 月制定的"到 2025 年建成年产 4 万吨高性能稀土永磁材料产能"的五年发展规划。 2025 年 1 月，公司根据市场需求并结合自身业务发展需要，投资建设"年产 2 万吨高性能稀土永磁材料绿色智造项目"，目前，该项目两个车间工程主体顺利通过 验收，力争到 2027 年建成 6 万吨稀土永磁材料产能。 投资者关系 江西金力永磁科技股份有限公司 投资者关系活动记录表 编号：2026-001 | | √特定对象调研 □媒体采访 | | □分析师会议 □业绩说明会 | | | | --- | --- | --- | --- | --- | --- | | 投资者关系 | □新闻发布会 | | □路演活动 | | | | 活动类别 | □现场参观 | | | | | | | □其他 | | （请文字说明其他活动内容） | | | | 形式 | 现场 | 网上 ☐ 姓名 | 电话会议 ☐ | | 机构名称 | | | 李柔璇 季熠 | | | 西部证券 华泰资产 ...

证券代码：300373 证券简称：扬杰科技 布局，通过并购补充优质产能、优化产能结构，支撑公司主业规模与持续发展， 不断丰富公司的半导体产业质态，实现公司整体规模和综合实力的快速提升。 Q：请介绍公司对工业方面在 2026 年景气度的预期。 A：从需求端来看，制造业设备以旧换新相关补贴政策的落地实施，将为行业释放 增量需求，为产业带来新的成长驱动力。加之前期 "两新"政策布局已形成扎实 积累，直接带动功率半导体下游应用需求扩容，多重利好预计会共同驱动工业板 块景气度稳步攀升。以上，从工业领域设备升级、效能提升的需求持续释放来看， 2026 年工业整体发展态势向好。 Q：公司 2026 年对汽车电子方面的展望。 A：公司汽车电子业务板块属于战略发展领域，未来将依托行业发展趋势及自身积 累，实现持续、较快增长。这一增长目标的实现，得益于公司自 2017 年起前瞻性 布局汽车电子专线所构建的体系能力、近年来通过多家国内外知名 Tier 1 厂商认 证并已与主流终端厂商展开战略合作所打下的市场基础，以及汽车电动化、智能 化转型所带来的持续行业机遇。基于现有基础，公司将持续加大汽车电子领域研 发投入，同时依托越南生产基 ...

Group 1: Future Development of Y-20 Transport Aircraft - The demand for large transport aircraft is expected to increase due to the modern concept of "globalization," which emphasizes intercontinental and high-speed deployment capabilities [2][3] - The Y-20 transport aircraft serves as a platform for air refueling, emergency rescue, and information support, contributing to a new industrial development path [3] - The aircraft plays a crucial role in civil logistics, humanitarian aid, and disaster response, establishing an "air lifeline" for global supply chain resilience [3] Group 2: International Cooperation and Competition - The company has developed a unique advantage in international subcontracting, focusing on differentiated competition and strategic complementarity with other major manufacturers [4] - Long-standing trust relationships with international giants like Airbus and Boeing in key structural components have resulted in high customer loyalty and replacement costs [4] Group 3: R&D Investment and Technological Innovation - The company prioritizes technological innovation, aligning with national R&D strategies and enhancing core technology development [5] - A dedicated innovation organization has been established to strengthen planning and increase funding for innovative projects, focusing on critical issues in current and future aircraft models [5] - The company aims to maximize the effectiveness of R&D resources to enhance product competitiveness and profitability [5] Group 4: Military Trade Progress - The company is actively advancing its military trade business, participating in international airshows to increase product visibility and engage with international clients [6] - Continuous communication with international customers is being conducted to facilitate the orderly development of military trade projects [6] Group 5: Production Capacity for C919 Aircraft - The company, as a key supplier for the C919 aircraft, currently has stable production capacity and meets the delivery requirements set by COMAC [6] - There are no existing production bottlenecks affecting the company's ability to support the C919 project [6]